Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.54 SEK | +7.21% | -1.67% | -5.30% |
May. 23 | Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy | CI |
May. 21 | Transcript : Cantargia AB, Q1 2024 Earnings Call, May 21, 2024 |
Sales 2024 * | - | Sales 2025 * | 578M 54.16M | Capitalization | 650M 60.98M |
---|---|---|---|---|---|
Net income 2024 * | -280M -26.26M | Net income 2025 * | -96M -9M | EV / Sales 2024 * | - |
Net Debt 2024 * | 56.6M 5.31M | Net Debt 2025 * | 657M 61.59M | EV / Sales 2025 * | 2.26 x |
P/E ratio 2024 * |
-1.64
x | P/E ratio 2025 * |
-1.89
x | Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.23% |
Latest transcript on Cantargia AB
1 day | +7.21% | ||
1 week | -1.67% | ||
Current month | +6.12% | ||
1 month | -0.84% | ||
3 months | +9.94% | ||
6 months | -5.30% | ||
Current year | -5.30% |
Managers | Title | Age | Since |
---|---|---|---|
Göran Forsberg
CEO | Chief Executive Officer | 61 | 14-07-08 |
Patrik Renblad
DFI | Director of Finance/CFO | 54 | 23-06-14 |
David Liberg
CTO | Chief Tech/Sci/R&D Officer | 55 | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Magnus Nilsson
BRD | Director/Board Member | 68 | 21-05-25 |
Chairman | 64 | 15-12-31 | |
Damian Marron
BRD | Director/Board Member | 62 | 21-05-25 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 3.54 | +7.21% | 788,010 |
24-05-23 | 3.302 | -4.84% | 303,690 |
24-05-22 | 3.47 | -4.14% | 371,287 |
24-05-21 | 3.62 | -3.98% | 790,435 |
24-05-20 | 3.77 | +4.72% | 464,578 |
Delayed Quote Nasdaq Stockholm, May 24, 2024 at 11:29 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-5.30% | 61.07M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- CANTA Stock